Avlayah (Tividenofusp Alfa)

Tividenofusp alfa is a medicine for children with Hunter syndrome, a rare genetic disease. It replaces an enzyme the body is missing and is built to reach the brain, to help protect thinking and development. It is given as an infusion into a vein.

Brand names:Avlayah
Medication

What people taking Avlayah (Tividenofusp Alfa) report

Every report comes from a Lived member, sent anonymously.

Have you tried Avlayah (Tividenofusp Alfa) for Hunter Syndrome (MPS II)?

NameHow it went

About Avlayah (Tividenofusp Alfa)

What It's For

Tividenofusp alfa, sold as Avlayah, is a weekly infusion for children with Hunter syndrome, also called mucopolysaccharidosis type II (MPS II). Hunter syndrome is a rare inherited condition, almost always in boys, in which the body lacks an enzyme needed to break down certain complex sugars. In its more severe form, the buildup affects the brain and leads to a gradual loss of learning, speech and other skills. Avlayah is approved in the US to treat the brain-related (neurologic) effects of Hunter syndrome in children who weigh at least 5 kg (about 11 pounds). It is meant to be started before neurologic impairment is advanced, including in children who do not have symptoms yet but are expected to develop them. It is a form of enzyme replacement therapy, the same broad approach as the older treatment idursulfase (Elaprase), but it is designed to reach the brain, which standard enzyme replacement largely cannot. The US approval, granted in March 2026, is an accelerated approval. That means it was based on a lab measure, a large drop in a storage substance in the spinal fluid, rather than on proof that children's development or abilities improve. A larger randomized trial is under way to confirm whether that benefit follows.

How It Works

In Hunter syndrome, a missing enzyme called iduronate-2-sulfatase means two sugar chains, heparan sulfate and dermatan sulfate, cannot be broken down. They build up inside cells throughout the body and in the brain, where the buildup is thought to drive the decline in thinking and development. Replacement enzyme given into a vein normally cannot get past the blood-brain barrier, the tight lining of brain blood vessels that keeps most large molecules out. Avlayah pairs the enzyme with an engineered antibody fragment that latches onto the transferrin receptor, a natural transport route the brain uses to bring in iron. The receptor carries the medicine across the barrier, and the enzyme then enters cells and clears the stored sugars. It also works in the rest of the body. In the main study, heparan sulfate in the spinal fluid fell by about 91% on average within 24 weeks, and most children reached the range seen in unaffected children. Researchers do not yet know how closely that drop translates into protected development.

Dosage & Administration

Avlayah is given once a week as an infusion into a vein, usually over about four hours. Treatment starts at a low dose that is raised in steps, about every four weeks, to a maintenance dose based on the child's weight. This gradual start is meant to reduce infusion reactions, and the dose is not raised if a step is not tolerated. Medicines such as antihistamines, fever reducers or steroids may be given beforehand for the same reason. The first infusions are given in a clinic or hospital equipped to treat a severe allergic reaction. Once a child is on the maintenance dose and handling it well, the care team may approve infusions at home under a healthcare provider's supervision. If a weekly dose is missed, it is skipped rather than doubled. Contact the care team to restart at the usual dose, then keep a weekly schedule from there.

Side Effects

Reactions linked to the infusion are very common. In the main study, almost 9 in 10 children had at least one, most often within the first two months. They can include fever, hives or rash, vomiting, chills, flushing, cough and headache, and can happen during the infusion, up to a day afterward, and sometimes several hours after a child gets home. The team usually manages them by slowing or pausing the infusion, adjusting premedication, or lowering the dose for a time. They tend to become less frequent with continued treatment. Children with heart or breathing problems from Hunter syndrome are watched more closely, because a reaction can be harder on them. Contact the care team promptly about a reaction that starts after leaving the infusion. Avlayah carries the strongest warning the US Food and Drug Administration uses, a boxed warning, for life-threatening allergic reactions (anaphylaxis). These can happen early in treatment or after a long time on it. Signs seen with Avlayah include wheezing, swelling of the lips or tongue, widespread hives, vomiting, a racing heartbeat and faintness from low blood pressure. If these occur during an infusion, the infusion staff stop it and treat the reaction; if they occur at home, call 911. Anemia (a low red blood cell count) was also common, usually appearing in the first three months and improving over time, sometimes with iron. Blood counts are checked before treatment and at three months. Report unusual tiredness or pale skin. Colds, ear infections, cough, diarrhea and minor falls or scrapes were also common in study children, many of whom were young.

Interactions & Warnings

Avlayah is not recommended together with other enzyme replacement therapy for Hunter syndrome, such as idursulfase (Elaprase), so the two are not taken together. No specific drug interactions are listed on the label, but the care team should still know about every medicine a child takes. One child in the studies developed membranous nephropathy, an immune-related kidney problem that lets protein leak into the urine. For that reason, kidney function and urine protein are checked during treatment. Nearly all treated children develop antibodies against the medicine. These lower the amount in the blood, but they did not reduce the drop in heparan sulfate at the standard dose in the study. Their long-term effect on benefit or safety is not yet known. Avlayah has only been studied in boys aged 3 months to 13 years. There is no information on its use in pregnancy or breastfeeding, and it has not been studied in children under 5 kg.

What to Expect

Avlayah is a long-term, weekly commitment. Early months involve the most visits, as the dose is built up, blood counts and kidney tests are checked, and the team learns how a child handles infusions. Infusion reactions are also most common in the first two months. The benefit Avlayah aims for is slowing or preventing the loss of skills, not reversing damage that has already happened, which is why the label calls for starting before neurologic impairment is advanced. Spinal fluid levels can fall within weeks, but whether a child's development is protected will only show over years of developmental assessment. In the long-term study, children's everyday skills stabilized or improved, but the study had no comparison group, so the size of the true benefit is still uncertain. Results from the ongoing randomized trial will matter for families deciding on and staying with this treatment. Avlayah does not replace the rest of Hunter syndrome care. Children still need regular follow-up for hearing, airway, heart, joints and development with their specialist team.

Questions to Ask Your Doctor

  1. 1.Is my child a good candidate for Avlayah given their current development, and what would we expect it to protect?
  2. 2.How would switching from Elaprase to Avlayah work, and what happens to treatment of the body symptoms?
  3. 3.How will we measure whether it is working over the coming months and years?
  4. 4.What premedication and monitoring will they have during the first infusions, and when could we move to home infusion?
  5. 5.What should we do if a reaction starts at home hours after an infusion?

Last reviewed • Oct 2026

Educational content, not medical advice.